Association of V227A PPARα polymorphism with altered serum biochemistry and alcohol drinking in Japanese men

Pharmacogenetics and Genomics

Volumn 16, Issue 8, 2006, Pages 569-577

  Naito, Hisao ^a   Yamanoshita, Osamu ^a   Kamijima, Michihiro ^a   Katoh, Takahiko ^b   Matsunaga, Tadashi ^c   Lee, Chul Ho ^a   Kim, Heon ^d   Aoyama, Toshifumi ^e   Gonzalez, Frank J ^f   Nakajima, Tamie ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^d Chungbuk National University College of Medicine   (South Korea)

^e SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Alcoholic liver disease; ALDH2; Cholesterol; Molecular epidemiology; Peroxisome proliferator activated receptor ; Polymorphism; SNP

Indexed keywords

ALANINE AMINOTRANSFERASE; ALDEHYDE DEHYDROGENASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; ALDH2 PROTEIN, HUMAN; PLASMA PROTEIN;

ADULT; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRINKING BEHAVIOR; ENZYME BLOOD LEVEL; ETHNOLOGY; EUROPE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; JAPAN; NORTH AMERICA; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PRIORITY JOURNAL; SERUM; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE; COMPARATIVE STUDY; EVALUATION; GENETIC LINKAGE; GENETICS; HEALTH STATUS; MALE;

RODENTIA;

ALCOHOL DRINKING; ALDEHYDE DEHYDROGENASE; BLOOD PROTEINS; GENE FREQUENCY; HEALTH STATUS; HUMANS; JAPAN; LINKAGE (GENETICS); MALE; POLYMORPHISM, GENETIC; PPAR ALPHA;

EID: 33746255676     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000220565.90466.79     Document Type: Article

References (46)

1. MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986; 6:221-232.
2. Diehl AM. Liver disease in alcohol abusers: clinical perspective. Alcohol 2002; 27:7-11.
3. Crabb DW, Galli A, Fischer M, You M. Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha. Alcohol 2004; 34:35-38.
4. Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, et al. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology 2004; 40:972-980.
5. You M, Crabb DW. Recent advances in alcoholic liver disease. II Minireview: molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol 2004; 287:1-6.
6. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347:645-650.
7. Auwerx J, Martin G, Guerre-Millo M, Staels B. Transcription, adipocyte differentiation, and obesity. J Mol Med 1996; 74:347-352.
8. Desvergne B, Michalik L, Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 2004; 18:1321-1332.
9. Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 2004; 61:393-416.
10. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137:354-366.
11. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46:1319-1327.
12. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273:25573-25580.
13. Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 1998; 246:370-374.
14. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393:790-793.
15. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 1993; 90:2160-2164.
16. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997; 94:4312-4317.
17. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995; 270:23975-23983.
18. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384:39-43.
19. Reddy JK, Chu R. Peroxisome proliferator-induced pleiotropic responses: pursuit of a phenomenon. Ann NY Acad Sci 1996; 804:176-201.
20. Tugwood JD, Aldridge TC, Lambe KG, Macdonald N, Woodyatt NJ. Peroxisome proliferator-activated receptors: structures and function. Ann NY Acad Sci 1996; 804:252-265.
21. Lieber CS, DeCarli LM. Animal models of chronic ethanol toxicity. Methods Enzymol 1994; 233:585-594.
22. Holden PR, Tugwood JD. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J Mol Endocrinol 1999; 22:1-8.
23. Sapone A, Peters JM, Sakai S, Tomita S, Papiha SS, Dai R, et al. The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 2000; 10:321-333.
24. Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, et al. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 2000; 43:673-680.
25. Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P, et al. Molecular scanning of the human PPARa gene: association of the L162V mutation with hyperapobetalipoproteinemia. J Lipid Res 2000; 41:945-952.
26. Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ, et al. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002; 22:805-810.
27. Lacquemant C, Lepretre F, Pineda Torra I, Manraj M, Charpentier G, Ruiz J, et al. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab 2000; 26:393-401.
28. Yamakawa-Kobayashi K, Ishiguro H, Arinami T, Miyazaki R, Hamaguchi H. A Val227Ala polymorphism in the peroxisome proliferator activated receptor alpha (PPARalpha) gene is associated with variations in serum lipid levels. J Med Genet 2002; 39:189-191.
29. IARC. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Ally Compounds, Aldehyde, Epoxides, and Peroxides. 1985. pp. 101-132.
30. Itoh T, Matsumoto M, Nakamura M, Okada A, Shirahashi N, Hougaku H, et al. Effects of daily alcohol intake on the blood pressure differ depending on an individual's sensitivity to alcohol: oriental flushing as a sign to stop drinking for health reasons. J Hypertens 1997; 15: 1211-1217.
31. Kitagawa K, Kawamoto T, Kunugita N, Tsukiyama T, Okamoto K, Yoshida A, et al. Aldehyde dehydrogenase (ALDH) 2 associates with oxidation of methoxyacetaldehyde: in vitro analysis with liver subcellular fraction derived from human and Aldh2 gene targeting mouse. FEBS Lett 2000; 476:306-311.
32. Yoshida A, Ikawa M, Hsu LC, Tani K. Molecular abnormality and cDNA cloning of human aldehyde dehydrogenases. Alcohol 1985; 2:103-106.
33. Yoshida A. Genetic polymorphisms of alcohol metabolizing enzymes related to alcohol sensitivity and alcoholic diseases. Alcohol 1994; 29:693-696.
34. Rzhetsky A, Ayala FJ, Hsu LC, Chang C, Yoshida A. Exon/intron structure of aldehyde dehydrogenase genes supports the 'introns-late' theory. Proc Natl Acad Sci USA 1997; 94:6820-6825.
35. Vasiliou V, Pappa A. Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease. Pharmacology 2000; 61:192-198.
36. Galli A, Pinaire J, Fischer M, Dorris R, Crabb DW. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver. J Biol Chem 2001; 276:68-75.
37. Maruyama K, Takeyama H, Nemoto E, Tanaka T, Yoda K, Matsunaga T. Single nucleotide polymorphism detection in aldehyde dehydrogenase 2 (ALDH2) gene using bacterial magnetic particles based on dissociation curve analysis. Biotechnol Bioeng 2004; 87:687-694.
38. Hara M, Wang X, Paz VP, Iwasaki N, Honda M, Iwamoto Y, et al. Identification of three missense mutations in the peroxisome proliferator-activated receptor alpha gene in Japanese subjects with maturity-onset diabetes of the young. J Hum Genet 2001; 46:285-288.
39. Nielsen EM, Hansen L, Echwald SM, Drivsholm T, Borch-Johnsen K, Ekstrom CT, et al. Evidence for an association between the Leu162Val polymorphism of the PPARalpha gene and decreased fasting serum triglyceride levels in glucose tolerant subjects. Pharmacogenetics 2003; 13:417-423.
40. Ishiguro H, Okubo Y, Ohtsuki T, Yamakawa-Kobayashi K, Arinami T. Mutation analysis of the retinoid X receptor, beta nuclear-related receptor 1, and peroxisome proliferator-activated receptor alpha genes in schizophrenia and alcohol dependence: possible haplotype association of nuclear-related receptor 1 gene to alcohol dependence. Am J Med Genet 2002; 114:15-23.
41. Lewis DF, Jacobs MN, Dickins M, Lake BG. Molecular modelling of the peroxisome proliferator-activated receptor alpha (PPAR alpha) from human, rat, and mouse, based on homology with the human PPAR gamma crystal structure. Toxicol In Vitro 2002; 16:275-280.
42. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 1997; 272:27307-27312.
43. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppressi on of apolipoprotein C-III. J Biol Chem 1995; 270:13470-13475.
44. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001; 12:297-304.
45. Lee GY, Kim NH, Zhao ZS, Cha BS, Kim YS. Peroxisomal-proliferator- activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level. Biochem J 2004; 378:983-990.
46. Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator- activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 2003; 278:27997-28004.